Detalles de la búsqueda
1.
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.
Cancer
; 126(6): 1175-1182, 2020 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31851385
2.
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.
Breast Cancer Res Treat
; 168(2): 349-355, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29190004
3.
Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen.
Acta Oncol
; 56(4): 614-617, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28080180
4.
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
JAMA
; 316(18): 1888-1896, 2016 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27825007
5.
Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up.
Breast Cancer Res Treat
; 138(2): 467-73, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23456195
6.
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy.
Breast
; 71: 63-68, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37517154
7.
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1.
Acta Oncol
; 50(3): 329-37, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21299448
8.
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
Acta Oncol
; 50(1): 35-41, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21174610
9.
The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer.
Acta Oncol
; 48(8): 1137-43, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19863221
10.
The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.
Clin Cancer Res
; 8(3): 811-6, 2002 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-11895913
11.
Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden.
Radiother Oncol
; 100(2): 167-75, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21752480
12.
TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
Acta Oncol
; 45(5): 590-6, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16864174
13.
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
J Clin Oncol
; 24(31): 4956-62, 2006 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17075113
14.
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial.
J Natl Cancer Inst
; 97(21): 1609-10, 2005 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-16264181
15.
Physical performance, toxicity, and quality of life as assessed by the physician and the patient.
Acta Oncol
; 41(1): 44-9, 2002.
Artículo
en Inglés
| MEDLINE | ID: mdl-11990517
Resultados
1 -
15
de 15
1
Próxima >
>>